Efrotomycin
is a narrow spectrum antibiotic. Among the genera tested for susceptibility in vitro it is most active against isolates of Moraxella, Pasteurella, Yersinia, Haeniophilus, Streptococcus and Corynebacterium. The drug is as active by oral administration as by the subcutaneous route.
Blood levels rise rapidly to high concentrations, after oral dosing, and are prolonged. Two peaks occur which may indicate biliary excretion and reabsorption. Urinary excretion is minimal.
The high blood concentrations explain, in part, the in vivo activity against pathogens such as Bordetella bronchiseprica which are relatively insensitive in vitro.
Oral activity of efrotomycin is an advantage over the related antibiotics, X-5108 and mocimycin.
Three related antibiotics X-51081), mocimycin2,3,MM, and kirromycin4),
were described in [1972] [1973] . Mocimycin and kirromycin are identical and antibiotic X-5108 is their N-methylated form').
Efrotomycin6 belongs to this family of antibiotics. It is a disaccharide derivative of antibiotic X-5108 (DEWEY, R. S. and G. ALBERS-SCHONBERG, personal communication).
The absolute structure of efrotomycin will be presented in a forthcoming paper.
In the present communication, we report some in vitro and in vivo activities of efrotomycin (greater than 90% pure), and some comparisons with antibiotic X-5108 and mocimycin are made.
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It is clear that efrotomycin is bactericidal with the -static and -cidal concentrations being much the same. Studies on the kinetics of the bactericidal action of efrotomycin have yielded some interesting results. In these experiments, the test bacteria for preparing the inoculum were grown in shaken culture OF ANTIBIOTICS in brain-heart broth for 16 hours at 37'C, the same conditions used for the inoculum in the antibacterial spectrum and bactericidal studies. Two test organisms, Moraxella bovis 418 and Pasteurella multocida 86, were used at two dilution levels in brain-heart broth. Cultures with and without antibiotics were incubated and sampled at intervals, and plate counts were made for survival determinations.
Effective killing of M. bovis 418 depends on the inoculum concentration and requires 6~8 hours at a concentration of 0.8 jig of efrotomycin/ml. At an efrotomycin concentration of 0.4 jig/nil the bacterial counts are fairly level for 6 hours before dropping for a short period (--.2 hours) prior to recovery and multiplication ( Figs. 1 and 2) . The relatively slow rate of kill by efrotomycin is also clear from the experiments with P. multocida 86 (Figs. 3 and 4) . Most interesting is the observation that the bacteria can grow for several hours in efrotomycin concentrations that eventually kill most of the population. Concentrations of 1.56, 3.12 and 6.25 pg/ml in Fig. 3 and concentrations of 3.12 and 6.25
/.rg/ml in Fig. 4 show this phenomenon.
The only published data on the mode of action of this class of compounds are those of WOLF et al.8 on kirromycin. This antibiotic is a potent inhibitor of bacterial protein synthesis by interfering with peptide transfer reactions associated with the elongation factor Tu. If this is the mechanism of action of efrotomycin as well, the effect is not immediately lethal except at relatively high concentrations of the drug.
In Vivo Activity
Efficacy against Mouse Infections
Mice were injected intraperitoneally with cultures grown for 16 hours at 37°C in brain-heart broth.
Efrotomycin, antibiotic X-5108 and mocimycin were dissolved in ethanol and diluted with 1 % Tween 80 in water (v/v). The other drugs were administered as sonicates in I % Tween, except for penicillin which was an aqueous solution. Five-tenths ml of drug was given by gavage or subcutaneously at the time of infection and 6 hours post infection. Groups of five CH female mice were used for each level and were observed daily for 7~14 days after infection. The ED50 and LD50were calculated by the method of KNUDSEN and CURTIS9) as mg/dose/mouse. The results are summarized in Table 3 .
Clearly, efrotomycin is rapidly absorbed after oral administration since it is as active by the oral route as by the subcutaneous route. and the subcutaneous LD50 is greater than 2 g/kg.
Plasma Concentrations
The oral efficacy of efrotomycin against B. bronchiseptica, which is relatively insensitive in vitro,
indicates that the antibiotic may be absorbed rapidly and reach and maintain high blood concentrations.
This possibility was tested experimentally.
Randomized groups of CF1 female mice were dosed by gavage with 4 mg of the sodium salt of efrotomycin per 20 g mouse. Blood was taken from the hearts at intervals using heparinized syringes and the plasma from each group was pooled and frozen until assayed. A microbiological cylinder agar plate diffusion assay was developed using M. bovis 418 as the test organism. Known concentrations of efrotomycin were prepared in normal mouse plasma and test samples were assayed against this standard.
The data are presented in Fig. 5 . The rapid absorption and prolonged high plasma levels of efrotomycin are evident. The two peaks of activity are most interesting. They have not been explained experimentally. However, biliary excretion of the drug followed by reabsorption is one possibility.
Serum Binding
Two ml volumes of 200jsg efrotomycin per ml of horse serum or saline were dialyzed in rotating chambers against 2 ml volumes of saline at 5°C for 48 hours.
The test was performed in quadruplicate.
Dialysates and dialysants were assayed for antibiotic content using appropriate standards and the M. bovis assay. Efrotomycin was 30% bound by horse serum under the conditions described.
Urinary Excretion
One reason for the prolonged blood levels of efrotomycin is the poor urinary excretion of the drug.
This was shown experimentally as follows: Five Marland Farms female rats, varying in weight from 190 to 210 g each was given efrotomycin by gavage at a dose of 400 mg/kg body weight. A control group of rats received an equal volume of diluent and was held under the same test conditions. Food and water were available during the test except that water was withheld for the first 6 hours after dosing. Urine was collected from 0~6 hours and from 6~24 hours. Samples from five rats were pooled and frozen until assayed. Standards were prepared in normal urine. 
